CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention
Steven R. Steinhubl, MD*,*,
Peter B. Berger, MD ,
Danielle M. Brennan, MS ,
Eric J. Topol, MD for the CREDO Investigators
* Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, Kentucky
Duke Clinical Research Institute, Duke University, Durham, North Carolina
Cleveland Clinic Foundation, Duke University, Durham, North Carolina
Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio
Manuscript received March 28, 2005;
revised manuscript received October 4, 2005,
accepted October 10, 2005.
* Reprint requests and correspondence: Dr. Steven R. Steinhubl, Division of Cardiovascular Medicine, 900 South Limestone, 326 Charles T. Wethington Building, Lexington, Kentucky 40536-0200. (Email: Steinhubl{at}uky.edu).
OBJECTIVES: This study sought to determine the optimal timing of a 300-mg clopidogrel loading dose before percutaneous coronary intervention (PCI) in patients enrolled in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
BACKGROUND: A loading dose of clopidogrel before a PCI has become relatively commonplace, although the data supporting this practice are limited and sometimes conflicting.
METHODS: Patients were randomized to receive either 300 mg clopidogrel or a matching placebo administered a minimum of 3 h and a maximum of 24 h before PCI. The primary 28-day combined end point was death, myocardial infarction, or urgent target vessel revascularization. Linear splines were used to summarize the effect of the time of pre-treatment as a continuous variable.
RESULTS: A total of 1,762 patients were evaluated. For patients randomized to placebo, there was no relationship between the duration of pre-treatment and the occurrence of the primary end point, whereas longer durations of pre-treatment in patients randomized to clopidogrel were associated with improved outcomes. The event rates diverged maximally at 24 h. The difference in outcomes between placebo and clopidogrel pre-treated patients was not significant until  15 h pre-treatment, with a 58.8% (p = 0.028) reduction in the primary end point in patients pre-treated with clopidogrel 15 h compared with placebo.
CONCLUSIONS: When a 300-mg loading dose of clopidogrel is used, little benefit is obtained compared with just 75 mg at the time of the PCI when the treatment duration is <12 h. In patients pre-treated for longer durations, the optimal duration seems to approach 24 h.
|
Abbreviations and Acronyms
| | GP = glycoprotein | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | UTVR = urgent target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano
Antithrombotics in acute coronary syndromes.
J. Am. Coll. Cardiol.,
September 8, 2009;
54(11):
969 - 984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Le May, G. A. Wells, C. A. Glover, D. Y. So, M. Froeschl, J.-F. Marquis, E. R. O'Brien, M. Turek, A. Thomas, M. Kass, et al.
Primary Percutaneous Coronary Angioplasty With and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Integrilin-Facilitated Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST)
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
330 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Lincoff, S. R. Steinhubl, S. V. Manoukian, D. Chew, C. V. Pollack Jr, F. Feit, J. H. Ware, M. E. Bertrand, E. M. Ohman, W. Desmet, et al.
Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
639 - 648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C Coons and S. Battistone
2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies
Ann. Pharmacother.,
July 1, 2008;
42(7):
989 - 1001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Nappi
Benefits and limitations of current antiplatelet therapies
Am. J. Health Syst. Pharm.,
July 1, 2008;
65(13_Supplement_5):
S5 - S10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell
The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
299S - 339S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
708S - 775S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Serebruany, V. Pasceri, G. Patti, G. Di Sciascio, F. von Lewinski, J. Riggert, W. Paulus, S. D. Wiviott, E. Braunwald, E. M. Antman, et al.
Prasugrel versus Clopidogrel
N. Engl. J. Med.,
March 20, 2008;
358(12):
1298 - 1301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol,
March 1, 2008;
28(3):
s33 - s38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O. O Braun, J. A. Jakubowski, A. Sugidachi, K. J. Winters, and A. Siegbahn
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Eur. Heart J.,
January 1, 2008;
29(1):
21 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bode and K. Huber
Antiplatelet therapy in percutaneous coronary intervention
Eur. Heart J. Suppl.,
January 1, 2008;
10(suppl_A):
A13 - A20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
e1 - e157.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. F. Bertrand, R. De Larochelliere, J. Rodes-Cabau, G. Proulx, O. Gleeton, C. Manh Nguyen, J.-P. Dery, G. Barbeau, B. Noel, E. Larose, et al.
A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation
Circulation,
December 12, 2006;
114(24):
2636 - 2643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Alfonso and D. J. Angiolillo
Platelet Function Assessment to Predict Outcomes After Coronary Interventions: Hype or Hope?
J. Am. Coll. Cardiol.,
November 7, 2006;
48(9):
1751 - 1754.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Cuisset, C. Frere, J. Quilici, P.-E. Morange, L. Nait-Saidi, J. Carvajal, A. Lehmann, M. Lambert, J.-L. Bonnet, and M.-C. Alessi
Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting
J. Am. Coll. Cardiol.,
October 3, 2006;
48(7):
1339 - 1345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hamdalla and S. R. Steinhubl
Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention
Eur. Heart J. Suppl.,
October 1, 2006;
8(suppl_G):
G20 - G24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
July 18, 2006;
48(2):
386 - 395.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl and R. Charnigo
Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough
JAMA,
April 5, 2006;
295(13):
1581 - 1582.
[Full Text]
[PDF]
|
|
|
|
